Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer
PHASE1CompletedINTERVENTIONAL
Enrollment
26
Participants
Timeline
Start Date
October 31, 2002
Primary Completion Date
May 31, 2006
Study Completion Date
January 31, 2007
Conditions
Esophageal CancerGastric Cancer
Interventions
DRUG
EMD 72000 (matuzumab) + ECX
Trial Locations (1)
Unknown
The Royal Marsden Hospital, London
All Listed Sponsors
lead
Merck KGaA, Darmstadt, Germany
INDUSTRY
NCT00113581 - Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer | Biotech Hunter | Biotech Hunter